EVFM Bio play. Over 14% short-float. Testing the 50 EMA at an area of resistance. We need to break over $1.40 and this could really fly. Lot's of recent insider buying and Large stake by Morgan Stanley. EVO100 Phase 3, Fast track approval. Results expected 2022. Expecting $3+.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.